The Analysis of The Effectiveness of Pulmonary Tuberculosis and HIV-Co-TB Treatment Therapies at Sulianti Saroso Infectious Diseases Hospital

Authors

  • Nurita Andayani Faculty of Pharmacy, Universitas Pancasila, South Jakarta 12640, Indonesia ,
  • Raise Maninda Faculty of Pharmacy, Universitas Pancasila, South Jakarta 12640, Indonesia ,
  • Rosa Marlina Department of Pulmonology and Respiratory Medicine, Sulianti Saroso Infectious Disease Hospital, North Jakarta 14340 Indonesia ,
  • Qoina Noviantani Faculty of Pharmacy, Universitas Pancasila, South Jakarta, Jakarta 12640, Indonesia ,
  • Khaled Qalalwa Palestinian Central Bureau of Statistics, Ramallah, Palestine, Higher Council for Innovation & Excellence (HCIE), Palestine ,

DOI:

https://doi.org/10.35814/jifi.v21i2.1282

Keywords:

DOTS, HIV tuberculosis, pulmonary tuberculosis, tuberculosis (TB)

Abstract

Mycobacterium tuberculosis causes Tuberculosis (TB), an infectious disease. The study aims to evaluate DOTS therapy's impact on pulmonary TB and TB-HIV patients. This research used a descriptive qualitative study design with a retrospective descriptive research approach using secondary  data for the period June 2017 to July 2020. The analysis uses the Miles and Huberman model. A study of 305 people found that 83% of pulmonary TB cases completed treatment within the initial phase, 64% completed the continuation phase. TB-HIV cases 93% completed treatment within the initial phase, 71% the continuation phase. The combination of OAT and ARV doses was successful in reducing initial smear conversion in pulmonary TB cases. The treatment was evaluated as cure in pulmonary TB cases, complete in pulmonary TB-HIV cases, and had no treatment failure status in both groups. Treatment success in pulmonary TB patients was not significantly related (p-value≥5%) with the type of OAT, type of PMO, gender, and age. Whereas in HIV co-infected pulmonary TB patients, treatment success was significantly related (p-value <5%) with the type of PMO, and not related (p-value≥5%) with the type of OAT, gender, and age.

References

Downloads

Published

2023-10-16

Issue

Vol. 21 No. 2 (2023): JIFI

Section

Articles

License

Licencing
All articles in Jurnal Ilmu Kefarmasian Indonesia are an open-access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License which permits unrestricted non-commercial used, distribution and reproduction in any medium.

This licence applies to Author(s) and Public Reader means that the users mays :

  • SHARE:
    copy and redistribute the article in any medium or format
  • ADAPT:
    remix, transform, and build upon the article (eg.: to produce a new research work and, possibly, a new publication)
  • ALIKE:
    If you remix, transform, or build upon the article, you must distribute your contributions under the same license as the original.
  • NO ADDITIONAL RESTRICTIONS:
    You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

It does however mean that when you use it you must:

  • ATTRIBUTION: You must give appropriate credit to both the Author(s) and the journal, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

You may not:

  • NONCOMMERCIAL: You may not use the article for commercial purposes.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.